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Purpose
The clinical status of HIV-1 infected patients initiated
on modern anti-retroviral (ARV) therapy is consistently
improved as indicated by reduced viral load (VL) and
increased CD4+ T-cell count, however, the reported
impact on patients’ health related quality of life
(HRQoL) has been variable. An appropriate assessment
o fH R Q o Lr e s p o n s eo v e rt i m ei nA R V - n a ï v eH I V - 1
infected subjects initiated on LPV/r combined with RAL
or TDF/FTC could reveal the impact of these therapies
on functional status and wellbeing.
Methods
The PROGRESS study is an ongoing, randomized, open-
label 96-week trial of LPV/r 400/100 mg BID combined
with either RAL 400 mg BID (n=101) or TDF/FTC 300/
200 mg QD (n=105) in ARV-naïve subjects. Subjects
completed the MOS-HIV, a validated, disease-specific
HRQoL instrument, at baseline and weeks 8, 24, and 48.
The MOS-HIV comprises 35 items in eleven dimen-
sions. Dimension specific scores and the two summary
scores (Physical Component Summary [PCS], Mental
Component Summary [MCS]) each range from 0 to 100
points, with higher scores indicating better function or
well being. Changes in score from baseline were ana-
lyzed using ANCOVA with the following covariates:
baseline score, treatment arm, gender, race/ethnicity,
age, time since HIV-1 diagnosis, baseline CD4+ T-cell
count, and plasma HIV-1 RNA level (VL).
Results
Both LPV/r + RAL and LPV/r + TDF/FTC treatment
arms achieved similar VL and CD4+ T-cell endpoints at
48 weeks; a similar proportion of subjects in each arm
discontinued the study prematurely. For each assess-
ment period, >79% of all subjects completed the MOS-
HIV survey. There were no statistically significant differ-
ences between treatment arms in MOS-HIV scores on
any dimension or summary score at any assessment per-
iod (p>0.100). When pooling data across all subjects,
MCS improved significantly from baseline at week 8
(mean change: +2.3, p = 0.013), week 24 (+3.5, p<0.001),
and week 48 (+2.2, p=0.041). PCS improved significantly
from baseline only at week 24 (+1.8, p=0.033). The Gen-
eral Health Perceptions dimension, an overall evaluation
of health, was significantly improved at week 8 (+5.4, p=
0.009), week 24 (+7.9, p<0.001), and week 48 (+6.0,
p=0.019).
Conclusions
LPV/r in combination with either RAL or TDF/FTC
improved HRQoL related to both mental and physical
states as well as overall health in ARV naïve, HIV-1
infected subjects at weeks 8, 24, and 48. Additional
HRQoL data through week 96 are being collected.
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